81 related articles for article (PubMed ID: 22864906)
21. Studies of the dysglycemic peptide, pancreastatin, using a human forearm model.
Cadman PE; Rao F; Mahata SK; O'Connor DT
Ann N Y Acad Sci; 2002 Oct; 971():528-9. PubMed ID: 12438174
[TBL] [Abstract][Full Text] [Related]
22. Current status on chromogranin A and pancreastatin.
Robberecht P; Lingier P; Woussen-Colle MC
Acta Gastroenterol Belg; 1993; 56(3-4):261-3. PubMed ID: 8266767
[TBL] [Abstract][Full Text] [Related]
23. Reversible hypopituitarism in patients with large nonfunctioning pituitary adenomas.
Arafah BM
J Clin Endocrinol Metab; 1986 Jun; 62(6):1173-9. PubMed ID: 3009521
[TBL] [Abstract][Full Text] [Related]
24. Analysis of pituitary hormones and chromogranin A mRNAs in null cell adenomas, oncocytomas, and gonadotroph adenomas by in situ hybridization.
Lloyd RV; Jin L; Fields K; Chandler WF; Horvath E; Stefaneanu L; Kovacs K
Am J Pathol; 1991 Sep; 139(3):553-64. PubMed ID: 1653518
[TBL] [Abstract][Full Text] [Related]
25. Pancreastatin: multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphism.
O'Connor DT; Cadman PE; Smiley C; Salem RM; Rao F; Smith J; Funk SD; Mahata SK; Mahata M; Wen G; Taupenot L; Gonzalez-Yanes C; Harper KL; Henry RR; Sanchez-Margalet V
J Clin Endocrinol Metab; 2005 Sep; 90(9):5414-25. PubMed ID: 15956083
[TBL] [Abstract][Full Text] [Related]
26. Pancreastatin producing cell line from human pancreatic islet cell tumor.
Funakoshi A; Tateishi K; Tsuru M; Jimi A; Wakasugi H; Ikeda Y; Kono A
Biochem Biophys Res Commun; 1990 Apr; 168(2):741-6. PubMed ID: 2159299
[TBL] [Abstract][Full Text] [Related]
27. Normal and adenomatous human pituitaries secrete thyrotropin-releasing hormone in vitro: modulation by dopamine, haloperidol, and somatostatin.
Le Dafniet M; Lefebvre P; Barret A; Mechain C; Feinstein MC; Brandi AM; Peillon F
J Clin Endocrinol Metab; 1990 Aug; 71(2):480-6. PubMed ID: 1974264
[TBL] [Abstract][Full Text] [Related]
28. Endocrinological outcome following first time transsphenoidal surgery for GH-, ACTH-, and PRL-secreting pituitary adenomas.
Kristof RA; Schramm J; Redel L; Neuloh G; Wichers M; Klingmüller D
Acta Neurochir (Wien); 2002 Jun; 144(6):555-61; discussion 561. PubMed ID: 12111488
[TBL] [Abstract][Full Text] [Related]
29. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study.
Vergès B; Boureille F; Goudet P; Murat A; Beckers A; Sassolas G; Cougard P; Chambe B; Montvernay C; Calender A
J Clin Endocrinol Metab; 2002 Feb; 87(2):457-65. PubMed ID: 11836268
[TBL] [Abstract][Full Text] [Related]
30. Elevated soluble epidermal growth factor receptor level in pituitary adenoma and carcinoma.
Kong YG; Ren ZY; Su CB; Wang RZ; Ma WB; Lian W
Chin Med Sci J; 2004 Sep; 19(3):199-202. PubMed ID: 15506648
[TBL] [Abstract][Full Text] [Related]
31. Pancreastatin, a presumed product of chromogranin-A (secretory protein-I) processing, inhibits secretion from porcine parathyroid cells in culture.
Fasciotto BH; Gorr SU; DeFranco DJ; Levine MA; Cohn DV
Endocrinology; 1989 Sep; 125(3):1617-22. PubMed ID: 2759035
[TBL] [Abstract][Full Text] [Related]
32. Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data.
Buurman H; Saeger W
Eur J Endocrinol; 2006 May; 154(5):753-8. PubMed ID: 16645024
[TBL] [Abstract][Full Text] [Related]
33. Pancreastatin: molecular and immunocytochemical characterization of a novel peptide in porcine and human tissues.
Schmidt WE; Siegel EG; Lamberts R; Gallwitz B; Creutzfeldt W
Endocrinology; 1988 Sep; 123(3):1395-404. PubMed ID: 3042370
[TBL] [Abstract][Full Text] [Related]
34. Soluble α-klotho: a novel serum biomarker for the activity of GH-producing pituitary adenomas.
Neidert MC; Sze L; Zwimpfer C; Sarnthein J; Seifert B; Frei K; Leske H; Rushing EJ; Schmid C; Bernays RL
Eur J Endocrinol; 2013 Apr; 168(4):575-83. PubMed ID: 23360820
[TBL] [Abstract][Full Text] [Related]
35. Prostaglandins inhibit secretion of histamine and pancreastatin from isolated rat stomach ECL cells.
Lindström E; Håkanson R
Br J Pharmacol; 1998 Jul; 124(6):1307-13. PubMed ID: 9720805
[TBL] [Abstract][Full Text] [Related]
36. Autocrine regulation of parathyroid secretion: inhibition of secretion by chromogranin-A (secretory protein-I) and potentiation of secretion by chromogranin-A and pancreastatin antibodies.
Fasciotto BH; Gorr SU; Bourdeau AM; Cohn DV
Endocrinology; 1990 Sep; 127(3):1329-35. PubMed ID: 2387256
[TBL] [Abstract][Full Text] [Related]
37. Chromogranin A and its role in the pathogenesis of diabetes mellitus.
Herold Z; Doleschall M; Kovesdi A; Patocs A; Somogyi A
Endokrynol Pol; 2018; 69(5):598-610. PubMed ID: 30074235
[TBL] [Abstract][Full Text] [Related]
38. Pancreastatin-like immunoreactivity in human carcinoid disease.
McGrath-Linden SJ; Johnston CF; O'Connor DT; Shaw C; Buchanan KD
Regul Pept; 1991 Mar; 33(1):55-70. PubMed ID: 2047545
[TBL] [Abstract][Full Text] [Related]
39. Gonadotroph cell adenomas of the pituitary.
Snyder PJ
Endocr Rev; 1985; 6(4):552-63. PubMed ID: 2416559
[TBL] [Abstract][Full Text] [Related]
40. Pancreastatin immunoreactivity in favourable childhood neuroblastoma and ganglioneuroma.
Kogner P; Bjellerup P; Svensson T; Theodorsson E
Eur J Cancer; 1995; 31A(4):557-60. PubMed ID: 7576967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
